SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

Title
: Integrating Data on Macrovascular and Microvascular Outcomes in Diabetes: Evolving Treatment Strategies
Activity/Course #:
: RealCME819430
Cost:
: Free
Release/Start Date:
: Oct 12 2017
Expiration Date:
: Oct 11 2018
Topics:
: Diabetes
Target Audience:
: Primary Care Providers
Format:
: RealCME
Estimated Time To Complete CME Activity:
: 1.0 Hours
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.50 pharmacology hour(s)
Hardware/Software Requirements:
Intensive therapy for tight glycemic control improves long-term outcomes in patients with T2DM. However, diabetes care is generally suboptimal, and up to two-thirds of people with T2DM do not achieve glycemic targets. T2DM patients are at increased risk for microvascular and macrovascular complications, depending upon the duration of diabetes and degree of hyperglycemia. The SGLT2 inhibitors are newer options for T2DM management that, unlike other antidiabetic agents, do not target insulin deficiency and resistance in T2DM, and therefore offer a different approach for managing this condition. Given their mechanism of action, the SGLT2 inhibitors can facilitate glycemic control while avoiding hypoglycemia, and promoting weight loss. They also exert beneficial effects on multiple cardiovascular and renal risk parameters, as demonstrated in recent trials, and may confer cardiovascular and renal protection. When used in combination therapy with other anti-diabetic agents for T2DM, the SGLT2 inhibitors can exert additive/synergistic effects.

This activity utilizes segments of a presentation by the faculty recorded at one of the Emerging Challenges in Primary Care symposia, to reinforce teaching points made during this program. Participants can expect to learn how to effectively integrate the SLGT2 class of medications into practice and the emerging data surrounding renal and macrovascular effects of diabetes treatments.

Learning Objectives
After completing this activity, the reader should be better able to:

1. Describe the role of the kidney in glucose metabolism in health and disease.
2. Review the physiologic effects and clinical efficacy of SGLT-2 therapy in various patient populations.
3. Review emerging data on possible renal and macrovascular effects of evidence-based diabetes treatment options .
4. Integrate the impact of treatment decisions on postprandial hyperglycemia and risk of hypoglycemia.

How To Obtain Your CME Certificate

  1. Read the learning objectives and faculty disclosures.
  2. Participate in the activity.
  3. Complete the post-test and activity evaluation.
  4. Physicians who successfully complete the post-test and evaluation will receive CME credit.
  5. Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
  6. You must score 60% or higher on the post-test to receive credit for this activity.
  7. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hours of continuing education (which includes 0.50 hours of pharmacology credit)
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure is provided below.

Robert S. Busch, MD, FACE serves as a speaker for Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Novo Nordisk, and Shire. Dr. Busch also serves as a researcher for Astra Zeneca, Novo Nordisk, Janssen, and Amgen.

Luigi Meneghini, MD, MBA serves as a consultant and advisory board member for Novo Nordisk and Sanofi Aventis.

Planning Committee
Gregg Sherman, MD has no real or apparent conflicts of interest to report.

Harvey Parker, PhD has no real or apparent conflicts of interest to report.

Joshua Kilbridge has no real or apparent conflicts of interest to report
Commercial Support
This activity is supported by educational funding provided by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.